Born 1974. Chairman of the Board since November 2014.
From November 2014, Henrik Rammer has been Chairman of the Board for all companies within Chordate. Henrik has many years of experience within private equity and worked for Axcel Management AB during the period 2008-2013 and for Triton Advisers (Sweden) AB from 2002 to 2007. Henrik currently works as a private investor at a number of different companies. BSc. degree from the London School of Economics, acquired in 1996.
Shares: 5 369 798Warrants: 1 280 000
Born 1955. Board member since June 2014.
Tommy Hedberg currently sits on the Boards of a number of different companies in Sweden. Tommy was CEO during the period 1998-2014 and before that was Head of Sales and Marketing at Atos Medical from 1990. Previously Head of Sales and Marketing at Medscand AB and Janssen Pharma AB. Studied chemical engineering followed by a post-secondary university education in economics, acquired in 1976.
Shares: 5 854 167Warrants: 1 585 896
Born 1963. Board member since April 2017.
Gunilla is CEO for Uppsala University's holding company UU Invest, and was previously CEO of Pharmanest AB. Gunilla has over 25 years of experience from different leading managerial posts within the pharmaceuticals and medical technology industries, including Deputy CEO at Q-Med AB. Gunilla holds an Executive MBA from Uppsala University, acquired in 1999, and a BSc. in Biomedicine from Uppsala University, acquired in 1985.
Shares: 0Warrants: 0
Born 1961. Board member since November 2014 and CEO since June 2017.
Anders Weilandt was CEO for Diabetes Tools Sweden AB from 2011-2016. Previously a member of the Board at Stille AB (publ) during the period 2004-2006, and also CEO from 2006-2009. Anders was CEO för Ascendia MedTech AB from 2000-2006. Anders currently has several Board assignments for various different companies. Medical electronics engineer. Anders holds an Executive MBA from Copenhagen Business School, which he acquired in 2004.
Shares: 548 708Warrants: 0
Öhrlings PricewaterhouseCoopers with authorized public accountant Henrik Boman as principal auditor.
We are a Swedish medical technology company listed on NGM Nordic SME.
Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.